Abstract:289 Objectives Phosphodiesterase 10A (PDE10A) is a potential therapeutic target for neurological diseases with striatal pathology, including Parkinson disease, Huntington disease and schizophrenia. PET radiotracers for PDE10A have been developed for in vivo assessing the PDE10A level and for target engagement for relevant therapeutic interventions. The aim of this study is to in vivo compare two potent and selective PDE10A radiotracers, [11C]TZ1964B and [18F]MNI659, in quantifying the expression of PDE10A in non-human primate (NHP) brain. Methods [11C]TZ1964B and [18F]MNI659 were used for double scans in the same NHP (totally 4 scans in 2 adult male cynomolgus monkeys, weighing 7-8 kg). The microPET was performed using a Focus 220 scanner, with an injection dose of ~10 mCi for each tracer. Binding potential (BP) of striatum was calculated to assess the radiotracer uptake using reference-based modeling (Logan Reference (LoganREF) model and simplified reference tissue model (SRTM)), with cerebellum as the reference. The striatum-to-cerebellum ratio of regional area under the time tissue-activity curve (AUC) was also calculated as a modeling-independent parameter for evaluating tracer uptake. HPLC metabolite analysis of NHP plasma was also performed for both the tracers. Results Both radiotracers showed high accumulation in NHP striatum. Striatal uptake of [11C]TZ1964B reached the max SUV value around 35 min post-injection (p.i.), while the peak of [18F]MNI659 appeared at ~10 min p.i.. Compared to [18F]MNI659, the tracer clearance of [11C]TZ1964B in the striatum was slower, probably due to differences in in vivo tracer metabolism. However, the washout in other (non-target) brain regions was similarly fast, indicating the target specificity and regional selectivity for both two tracers. The BP estimates of [11C]TZ1964B were 3.72 by LoganREF and 4.39 by SRTM; the values for [18F]MNI659 were 5.08 by BP-LoganREF and 5.33 by BP-SRTM. AUC ratios of these two tracers were 5.87 for [11C]TZ1964B and 7.60 for [18F]MNI659. Based on the BP-LoganREF and BP-SRTM data in NHP striatum, coefficients of variation were ~10% for [11C]TZ1964B and ~30% for [18F]MNI659. Additionally, the in vivo tracer metabolism study showed, at 60 min p.i., the percentage of parent compounds were ~70% for [11C]TZ1964B and ~50% for [18F]MNI659. Conclusions Both [11C]TZ1964B and [18F]MNI659 could serve as suitable PET radiotracers for assessment of PDE10A in the brain, regardless of differences in in vivo tracer characteristics. Due to the half-life of radiotracers, the C-11 tracer could be utilized for multiple injections for patients in the same day, while the F-18 tracer have commercial distribution advantage that allows delivery to multiple sites with 3-4 hrs drive distance. Further studies will compare these two tracers in human subjects. Research support: NIH/NIMH #MH092797 and NIH/NINDS #NS075527, #NS061025. References: 1. Barret, et al. Journal of Nuclear Medicine, 2014, 55:1297-1304; 2. Liu, et al. NeuroImage, 2015, 121:253-262.

Synthesis and initial evaluation of radioiodine-labelled deuterated tropane derivatives targeting dopamine transporter

Synthesis and biological evaluation of 18 F-labelled deuterated tropane derivatives as dopamine transporter probes

Comparable Investigation in Dopamine Transporters with 99Mtc-Trodat-1 and 131I-FP-CIT SPECT in Parkinson's Disease Patients

Imaging Study of Brain Dopamine Transporter Imaging Agent ~(99)Tc~m-Trodat-1

Synthesis and Evaluation of 18F-Labeled Phenylpiperazine-like Dopamine D3 Receptor Radioligands for Positron Emission Tomography Imaging

Design, synthesis, and characterization of a novel, 4-[2-(diphenylmethoxy)ethyl]-1-benzyl piperidine-based, dopamine transporter photoaffinity label

Evaluation of damage discrimination in dopaminergic neurons using dopamine transporter PET tracer [18F]FECNT-d4

18 F-Labeled PET Tracers Specific for Adenosine A 2A Receptor: Design, Synthesis, and Biological Evaluation

Highly Efficient Radiosynthesis and Biological Evaluation of [18 F]Safinamide, a Radiolabelled Anti-Parkinsonian Drug for Positron Emission Tomography Imaging.

SPECT Imaging Study of the Biodistribution of Beta － CIT in the Whole－ Body of Healthy Rhesus Monkeys

First-in-human study of D6-[18F]FP-(+)-DTBZ, a novel VMAT2 tracer: whole-body biodistribution and brain PET comparison with [18F]FP-(+)-DTBZ (AV-133)

Preparation of a Dopamine Transporter Imaging Agent ~(18)F-Fp-β-cit and Its Biodistribution in Rat Brain

Synthesis and characterization of iodobenzamide analogues: potential D-2 dopamine receptor imaging agents

A Novel PET Tracer 18F-Deoxy-thiamine: Synthesis, Metabolic Kinetics, and Evaluation on Cerebral Thiamine Metabolism Status

In vivo studies of the SERT-selective [18F]FPBM and VMAT2-selective [18F]AV-133 radiotracers in a rat model of Parkinson's disease

Comparison of Two Pde10a Radiotracers, [11c]tz1964b and [18f]mni659 in the Brains of Non-Human Primates

125I-Β-cit Imaging Study of Striatal Dopamine Transporters in Mice Model of Parkinsonism

Development and Preliminary Evaluation of an Aryl 18F-Labeled PET Tracer for Imaging PDE10A

In vitro evaluation of [3H]PI-2620 and structural derivatives in non-Alzheimer's tauopathies

Preclinical evaluation of [18F]FP-CIT, the radiotracer targeting dopamine transporter for diagnosing Parkinson's disease: pharmacokinetic and efficacy analysis

Radiosynthesis and Preclinical Evaluation of an 18F-Labeled Triazolopyridopyrazine-Based Inhibitor for Neuroimaging of the Phosphodiesterase 2A (PDE2A)